NHAS
RXRX icon

Novo Holdings A/S’s Recursion Pharmaceuticals RXRX Stock Holding History

Novo Holdings A/S’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,929,835
Closed -$38.7M – 27
2025
Q3 		$38.7M Sell
7,929,835
-1,735,293
-18% -$9.11M 2.49% 13
2025
Q2 		$48.9M Hold
9,665,128
– – 3.45% 8
2025
Q1 		$51.1M Sell
9,665,128
-449,505
-4% -$3.28M 3.89% 8
2024
Q4 		$68.4M Buy
+10,114,633
New +$68M 4.14% 7

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Novo Holdings A/S's RXRX Position: Q4 2025 in Review

Novo Holdings A/S sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 7,929,835 shares — an estimated $38.7M sold.

Novo Holdings A/S first reported a position in RXRX in Q4 2024 and held it in 4 quarters. The position peaked at $68.4M in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Novo Holdings A/S reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Novo Holdings A/S sold 7,929,835 Recursion Pharmaceuticals shares in Q4 2025, an estimated $38.7M.
  • Novo Holdings A/S first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Novo Holdings A/S's Recursion Pharmaceuticals position peaked at $68.4M in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Novo Holdings A/S's 13F filing for Q4 2025, filed 17 Feb 2026.